Shanghai, China - On June 7, Professor Patel, the world's top expert in robot-assisted surgery, founder and chairman of the Society of Robotic Surgery (SRS), visited Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot®). During the visit, Prof. Patel tried out all of MicroPort^® MedBot®'s current robotic products for clinical application, and also experienced 5G remote surgery simulation. He also had in-depth discussions with Mr. Hongbin Sun, Chief Financial Officer of MicroPort^® Group and Chairman of MicroPort^® MedBot®, Jonathan Chen, Chief International Business Officer of MicroPort^® Group, Dr. Chao He, President of MicroPort^® MedBot®, and Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot®, on new trends in the field of surgical robots and the application of 5G-based remote surgery.

17,000 robot-assisted prostatectomies completed, and visits made by top urologists worldwide to MicroPort^® MedBot®

Professor Vipul Patel is a highly experienced urologist in robot-assisted surgery worldwide. As one of the pioneers in robot-assisted surgery and advanced minimally invasive surgical techniques, Professor Patel is close to completing 17,000 robot-assisted prostatectomies. He has published numerous articles and books related to robot-assisted surgery, prostate cancer and kidney treatment, including "Robotic Prostatectomy: A Portable Guide" and "Robotic Laparoscopic Surgery and Endoscopic Anatomy" on this basis. It can be said that Professor Vipul Patel has made outstanding contributions to the advancement of robot-assisted surgery and the improvement of surgical outcomes for the patients concerned.

Passionate about innovative surgical techniques and procedures, Professor Patel also founded the Society of Robotic Surgery (SRS), aiming to promote robot-assisted surgery and train robotic surgeons.

For his outstanding achievements in the field of robot-assisted surgery, Professor Patel has been hailed by his international peers as one of the best and most influential surgeons in the history of modern medicine.

Accelerated rise of Chinese-developed surgical robots, bringing more choices to the world

During the visit to the Toumai^® Robot showroom, Dr. Chao He introduced the performance of Toumai^® Robot and the clinical validation procedures currently being performed. He said that Toumai^®, as China's first independently developed and approved four-arm endoscopic surgical robot, has completed more than 900 difficult surgical procedures in urinary surgery, thoracic surgery, hepatobiliary and pancreatic surgery, gynecology and gastrointestinal surgery in clinical application, helping clinical experts achieve many breakthroughs up from zero for many Chinese-developed surgical robots, and showing the high clinical application value of Toumai^® Robot.

In the 5G-based remote surgery, Dr. Chao He said that after strict and sufficient technical argumentation, animal experiments, and scientific and ethical demonstration, Toumai^® Robot and Honghu Orthopedic Surgical Robot have assisted medical staff in multiple locations to complete dozens of 5G-based remote surgeries. MicroPort^® MedBot® is by now the surgical robot company that has successfully completed remote clinical surgeries in most departments (including urology, thoracic surgery, hepatobiliary and pancreatic surgery, gastrointestinal surgery, and orthopedics) with its products worldwide, demonstrating the performance of Chinese-developed surgical robots and the superiority of 5G technology.

The outstanding performance of Toumai^® and Honghu marks the maturity of Chinese-developed surgical robots in clinical applications and their ability to meet high clinical quality requirements, and also indicates that "Made in China" has reached the international advanced level, which will accelerate the replacement of imports by Chinese-developed ones and thus benefit more patients.

Professor Patel tried out Toumai^® four-arm endoscopic surgical robot, Toumai^® single-arm endoscopic surgical robot, Mona Lisa prostate puncture robot and R-ONE^® vascular interventional robot. Under his control, Toumai^®'s four robotic arms moved in and out in an orderly and flexible manner, completing surgical operations such as stripping, cutting, suturing and knotting smoothly. Professor Patel also praised the experience from time to time during 5G-based remote simulation,

saying that Toumai^® robot provides a good feel for the operation on both master and slave sides with almost no latency, creating an experience close to performing robot-assisted surgery in the field. The success of medical staff in China using 5G technology to perform remote surgery means that ultra-remote robot-assisted surgery will be normalized in the future. In addition to upgrading local medical services, it can also provide valuable teaching assistance and improve the skills of surgeons in remote areas.

He said that China's surgical robot market started late but developed rapidly, and that relying on technological innovation and local advantages, Chinese companies have developed a number of surgical robots on their own, which will undoubtedly bring more benefits to patients if they can break the current monopoly of the market to give medical staff more choices.

Dr. Chao He agreed with Professor Patel's view on the rapid development of China's robot industry. He said the rapid growth of MicroPort^® MedBot® in recent years can be attributed to two main factors. First, MicroPort^® MedBot® focuses on the development of core underlying technologies related to surgical robots. Since the underlying technologies of surgical robots are the same, we can develop other types of surgical robots with half the effort if the core technology of the endoscopic surgical robot is mastered. Second, MicroPort^® MedBot® has always insisted on medical-industrial cooperation to optimize its products under the spirit of pioneering and innovation since its establishment. We have a very intensive cooperation with Chinese surgeons. By listening to surgeons' clinical surgery feedback, we adjust and optimize product functions in a timely manner, and promote industrial upgrading and product iteration to make it closer to surgeons' clinical surgery needs.

Professor Patel concluded his visit with a warm invitation to MicroPort^® MedBot® to international academic conferences such as SRS, and to showcase products such as Toumai^® to the world, so that clinical experts around the world can enjoy the technological innovation of Chinese surgical robots together.